Rosay - PICC, port and PIV in oncology

(1)

(2)

• 

• _{Bard: Congress, Research, Consultant, Education}

(3)

(4)

(5)

1.  Long-term survival

2.  Quality of life

3.  Good functional status

For the patient

(6)

(7)

(8)

What is quality for Central Venous access?

Quality Device Team Organization Efficacy Security Efficiency Equity Reactivity Quality With cortesy of Pr M RIVOIRE Device Team Organization Device Team

Organization Device _Team

Organization

Device Team

(9)

(10)

(11)

(12)

Therapy

(13)

(14)

(15)

(16)

(17)

(18)

Background

‒  High frequency of CVA complications

‒  In oncology CVA complications have great impact

on cancer treatment

Devices

(19)

Potential of complications

(20)

(21)

(22)

(23)

(24)

(25)

13,6%

11,9%

(26)

(27)

(28)

(29)

We need datas…

(30)

Ressources available for devices’

implantation and care.

(31)

(32)

(33)

(34)

(35)

(36)

(37)

(38)

(39)

(40)

(41)

(42)

(43)

(44)

(45)

In the real life…

(46)

(47)

(48)

(49)

(50)

(51)

Primary and or adjuvant chemotherapy PICC Short term <4 months Palliative Chemotherapy for advanced or palliative patients TIVAD Long life expectancy Chemotherapy and

(52)

(53)

(54)

(55)

(56)

(57)

(58)

(59)

(60)

Cancer Treatments’ evolutions

BREAST CANCER ADJUVANT

TREATMENT Subcutaneous TRANSTUZUMAB _{reduces lenght I.V. adjuvent CT}

LUNG CANCER

Increased efficacy of oral Therapy For NSCLC

- Molecular Target Therapy - EGFR/ALK inihibitors

(61)

(62)

(63)

Patie

nt ce

(64)

• Device choice should be patient centered

• _{Requires the input of a multi disciplinary team}

• Should ensure the prevention of dammage

(65)

Life hangs by a thread

http://tamarafowler.blogspot.fr/

Rosay - PICC, port and PIV in oncology

•

•

Bard: Congress, Research, Consultant, Education

1. Long-term survival

2. Quality of life

3. Good functional status